Brief: Boehringer Ingelheim To Evaluate Combination Of Dll3‑Targeting T‑Cell Engager Plus Pd‑L1/Vegf‑A Bispecific Antibody In Small Cell Lung Cancer
09/04/2026 13:41
April 9 (Reuters) - BioNTech SE 22UAy.DE: BOEHRINGER INGELHEIM: TO EVALUATE COMBINATION OF DLL3‑TARGETING T‑CELL ENGAGER PLUS PD‑L1/VEGF‑A BISPECIFIC ANTIBODY IN SMALL CELL LUNG CANCER BOEHRINGER INGELHEIM: BIONTECH WILL SUPPLY PUMITAMIG AND CO WILL BE REGULATORY SPONSOR OF PHASE IB/II STUDY BOEHRINGER INGELHEIM: BIONTECH AND CO RETAIN FULL RIGHTS TO THEIR RESPECTIVE ASSETS, AND AGREEMENT IS MUTUALLY NON-EXCLUSIVE BOEHRINGER INGELHEIM: TRIAL WILL BEGIN DOSING PATIENTS IN SECOND HALF OF 2026 Source text: ID:nGNX7RHYs Further company coverage: [22UAy.DE] ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bristol-Myers Squibb Co
See all newsFactbox: Major deals involving US drugmakers and biotechs over the past decade
Brief: Bristol Myers Squibb Announces Dividend
Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial
Factbox: Major deals involving US drugmakers and biotechs over the past decade
Izalontamab Brengitecan Shows Significant OS And PFS Improvements In TNBC And ESCC